|
Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer Clinical research trials and Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer. Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer  Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
For Condition: Fallopian Tube Neoplasms,Peritoneal Neoplasms,Ovarian Cancer
Status: Recruiting
Sponsor(s): Bristol-Myers Squibb , ImClone Systems
Synopsis: To determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - Subject with histologically documented ovarian, peritoneal or fallopian tube cancer, Stage III or IV following initial surgery, which is EGFR-positive by IHC (may be based on archival samples) and is metastatic - Prior appropriate surgery for ovarian, peritoneal or fallopian tube cancer - Subjects must be entered no more than 12 weeks postoperatively Exclusion Criteria - Subjects with current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas) who have received prior radiotherapy to any portion of the abdominal cavity or pelvis - Prior history of therapy which targets the EGFR pathway or prior history of chimerized or murine monoclonal antibody therapy - Subjects who have received prior chemotherapy for any abdominal or pelvic tumor
Total Enrollment: 39
Location and Contact Information:
MD Anderson Cancer Center *Not yet recruiting*
Houston, Texas, 77030
United States
Not yet recruiting David Gershenson 713-745-2565
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Carol Aghajanian 212-639-2252
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting Russell Schilder 215-728-3545
Additional Information:
Study ID Numbers: CA225-009 ST;
Study Start Date: September 2003
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00063401
Other Peritoneal Neoplasms Studies:
1. Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) with Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis
2. Phase II Trial of Gleevec in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
3. EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
4. Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Related Studies:
Other Peritoneal Neoplasms Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
|
|
|
|
|
|
|
|
